Company / Cost of Revenue
Gilead Sciences Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.2B
FY2025
5-year range
$4.6B / $6.6B
FY2021-FY2025
Trend
-0.3%
vs FY2024
Sector context
#10 of 85
Health Care
What the data says
Gilead Sciences's cost of revenue of $6.2B is higher than 88% of companies in the Health Care sector (FY2025). Cost of Revenue has fluctuated over the past 10 years, ranging from $3.8B in FY2016 to $6.6B in FY2023.
Based on SEC 10-K filings.
$6.2B in FY2025 with a 5-year CAGR of +6.4%. Top quartile in the Health Care sector.
Improved from $6.6B to $6.2B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +10.9%
- 5-Year CAGR
- +6.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 85This company $6.2B Sector average $2.0B
▼
+214.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +6.4%, indicating consistent growth.
- In FY2025, cost of revenue decreased 0.3% year-over-year.
- Ranks #10 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.2B | -0.3% |
| FY2024 | $6.3B | -5.3% |
| FY2023 | $6.6B | +44.4% |
| FY2022 | $4.6B | -2.2% |
| FY2021 | $4.7B | +2.3% |
| FY2020 | $4.6B | +4.6% |
| FY2019 | $4.4B | +2.6% |
| FY2018 | $4.3B | +6.4% |
| FY2017 | $4.0B | +5.8% |
| FY2016 | $3.8B | -5.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026